Opendata, web and dolomites

SpheroPredict

A 3D advanced test for prediction of drug response in secondary liver cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SpheroPredict project word cloud

Explore the words cloud of the SpheroPredict project. It provides you a very rough idea of what is the project "SpheroPredict" about.

patient    causes    efficient    chemotherapy    spherotec    productivity    heterogeneous    feasibility    created    treat    burden    quality    entail    patients    line    dealing    therapies    drug    deathliest    trial    risked    therapy    micro    predict    century    metastatic    options    secondary    commercialisation    healthcare    migrating    proven    individualised    survival    installing    error    model    published    economic    warrant    accurate    commercial    financial    treatment    platform    locations    efficacy    tumours    incurred    regarding    chemoresistance    treatments    tumour    spheropredict    era    worldwide    biologically    cycle    de    spheroid    fail    clear    life    inefficient    perspectives    death    cancers    types    primary    cells    medicine    solution    liver    3d    innovative    21st    guideline    guidelines    personalised    body    diseases    cancer    metastasizing    urgent    international    deaths    drugs    time    lack    alleviate    risk    toxicity    designed    first   

Project "SpheroPredict" data sheet

The following table provides information about the project.

Coordinator
SPHEROTEC GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: MARTINSRIED
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.spherotec.com/ - www.spheromed.com - www.spheroselect.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SPHEROTEC GMBH DE (MARTINSRIED) coordinator 50˙000.00

Map

 Project objective

Cancer remains one of the deathliest diseases of the 21st century, with more than 1.9 M deaths per year in Europe. Some tumours entail a high risk of metastasizing, meaning that they are able to reach other locations in the body. Migrating cells from a primary tumour often cause secondary cancer in the liver, which is one of the leading causes of death worldwide.Regarding treatment options, international institutions have published clear guidelines about first line treatments to treat particular types of primary cancers. However, when dealing with secondary cancers (like metastatic liver cancer) there is a heterogeneous and very wide range of treatment options and no clear guidelines. The choice of treatment in secondary cancer is based in “trial and error”. This “trial and error” approach causes many patients fail to respond to therapy due to chemoresistance (lack of response to chemotherapy). In response, we at SpheroTec have created SpheroPredict, an individualised drug testing platform designed to predict the patient’s response to guideline therapies before installing the treatment cycle. Using cancer cells from the patient’s tumour, we build an accurate and biologically relevant 3D micro-tumour (spheroid) model to test the drugs and analyse the response in advance. In the end, only drugs with proven efficacy and low toxicity will be applied in the patient’s therapy cycle. In the era of personalised medicine and with the urgent need for de-risked and efficient drug treatments, we have developed an innovative solution that will greatly improve the patient’s survival time, quality of life and will help to alleviate the economic burden on the EU healthcare system incurred by inefficient therapies and productivity loss. Thus, in Phase 1, we aim to warrant the feasibility of the SpheroPredict project from the technical, commercial and financial perspectives, in order to ensure its success upon commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPHEROPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPHEROPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More